Davis, California, USA, August 2025 — Sarah F. has been named Chief Financial Officer at Antibodies Incorporated, a pivotal addition to the leadership team of this life sciences company. With over 17 years of finance and business operations experience, Sarah brings depth and breadth across diagnostics, aerospace, technology, and consumer products sectors.
Sarah most recently held the position of Senior Manager, Financial Planning & Analysis at Beckman Coulter Diagnostics for over six years, where she played a vital role in shaping corporate finance strategy and business planning. Prior to that, she spent three years at Oracle, serving as Financial Controller for both North America Applications, Oracle Marketing Cloud, and North America Hardware & Manufacturing divisions. Her ability to align financial strategy with operational priorities was further demonstrated during her tenure at SpaceX as Finance and Accounting Manager, where she supported financial operations during a period of extraordinary growth.
In the earlier phase of her career, Sarah gained foundational experience with roles at Goldman Sachs as a Financial Analyst, Mattel as a Senior Financial Analyst, and in audit and advisory at EY and PwC. Each role added layers of expertise, from financial analysis and corporate finance to compliance and treasury—culminating in a well-rounded financial leadership profile.
In her new role as CFO of Antibodies Incorporated, Sarah will oversee the company’s financial planning, compliance, capital management, and governance structures. Her appointment reflects the organization’s commitment to operational excellence and strategic stewardship in supporting scientific research and customer success.
Headquartered in Davis, California, USA, Antibodies Incorporated unites trusted life science brands—Antibodies Inc, Aves Labs, ImmunoChemistry Technologies, and PhosphoSolutions—offering highly validated neuroscience antibodies and custom services. Known for pioneering innovations like NeuroMab monoclonal antibodies and chicken polyclonal antibody development, the company delivers high-quality solutions for ELISA, IHC, and cell viability research, supporting breakthrough science across labs worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
